GLP-1

News

Gene variants could explain why some people lose more weight than others with GLP-1 drugs, and why some are more prone to side effects.

News

Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.

News

Novo Nordisk is facing generic semaglutide in India, Atrogi is testing a new weight loss approach, and Structure has more data with its oral GLP-1.

News

Novo Nordisk and Hims & Hers have set their differences aside, agreeing to work together once again on the sale of GLP-1 agonists.

News

Eli Lilly has added another channel to its selling options for obesity therapy Zepbound in the US, launching a programme directed at employers.

News

New research has lent weight to the intriguing idea that GLP-1 agonists may help people with substance use disorders break their addiction.